1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grants2026 Mars Shot Lobular Breast Cancer Alliance Grant is sponsored by Society of Nuclear Medicine and Molecular Imaging (SNMMI) and Lobular Breast Cancer Alliance. This opportunity supports mission-aligned projects and measurable outcomes.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Mars Shot Research Fund Awards SNMMI LBCA Invasive Lobular Carcinoma Fellowship - The Lobular Breast Cancer Alliance Mars Shot Research Fund Awards SNMMI LBCA Invasive Lobular Carcinoma Fellowship The $100,000 SNMMI / LBCA Invasive Lobular Carcinoma Imaging Research Fellowship for the 2025 Marsh Shot Fund has been awarded to Randy Yeh, MD, a radiologist and nuclear medicine physician at Mount Sinai Health System, associate professor of radiology, and chief of nuclear medicine at Icahn School of Medicine at Mount Sinai in New York.
Yeh’s one-year ILC imaging research grant was awarded based on his proposal, “Improving detection and outcomes in patients with metastatic invasive lobular breast cancer through novel FAPI PET imaging.
” Yeh and colleagues believe that 18 F-FAPI PET/CT—which targets fibroblast activation protein found on the surface of cancer-associated fibroblasts that are abundant in the supportive tissue of ILC tumors—could be a better imaging option to detect ILC than CT, bone scans, or 18 F-FDG PET.
Yeh’s study will assess and compare the ability of FAPI PET and FDG PET to detect tumors, focusing on detection rates, image clarity, and signal intensity. LBCA is pleased to once again partner with SNMMI on ILC imaging research grant award through the Mars Shot Fund. The Mars Shot Fund was established in 2023 as a forward-looking glimpse into the future of nuclear medicine.
It provides resources that translate visionary nuclear medicine imaging, radiopharmaceutical therapy, and data science research or projects into tools or treatments that will help improve the lives of patients. To read the full award announcement, click here. JOIN US for a Lobular Breast Cancer Chat with Dr. Randy Yeh to learn more about his research and the joint effort with research advocate Gitte Joergensen to develop the proposal.
Also included will be a discussion about the Mars Shot program and how LBCA and SNMMI have partnered together to fund initiatives focused on ILC research with Dr. Gary Ulaner, LBCA SAB member and Director, Molecular Imaging and Therapy at Hoag Family Cancer Institute. " * " indicates required fields This field is for validation purposes and should be left unchanged.
According to the current listing, eligibility includes: Open to researchers worldwide; application requires a detailed research plan and NIH biosketch. Confirm the full requirements in the official notice before applying.
The current listing shows $100,000. Verify award ceilings, matching requirements, and allowable costs in the official notice.
The published deadline was August 14, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
2026 Mars Shot Lobular Breast Cancer Alliance Grant is funded by Society of Nuclear Medicine and Molecular Imaging (SNMMI) and Lobular Breast Cancer Alliance. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
The NIH Common Fund launched PRIMED-AI — Precision Medicine with AI: Integrating Imaging with Multimodal Data — as five coordinated funding opportunities (RFA-RM-27-011 through -015) that build a full pipeline from standards to clinic. Here is how the Playbook, Data-to-Model partnerships, Model-to-Clinic translation, Validation Center, and Logistics Center fit together, what each pays, who is eligible, and how to position before the October 2026 deadlines.
Read articleCDMRP reissued the FY26 BCRP Breakthrough Award Levels 1 and 2 and the Clinical Research Extension Award on September 3, 2026, with a November 4 pre-application deadline and a November 18 full application deadline. Round one closed July 8. The arithmetic across both windows accounts for nearly the entire FY26 appropriation — which tells you what kind of second chance this is.
Read articleThe Rural Utilities Service published the ARC Program on September 14, 2026. Same IRA Section 22004 authority that carried the $9.7 billion New ERA program, redirected to nuclear power supply and transmission efficiency. Letters of Interest open October 19 and close November 20.
Read article